<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:department>Sch of Biological Sciences</gtr:department><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/905A7C93-5D41-4449-80D2-D174055C5C45"><gtr:id>905A7C93-5D41-4449-80D2-D174055C5C45</gtr:id><gtr:name>Countess of Chester Hospital NHS Trust</gtr:name><gtr:address><gtr:line1>Countess of Chester Hospital</gtr:line1><gtr:line2>Liverpool Road</gtr:line2><gtr:postCode>CH2 1UL</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/724904C3-EB9D-4C9F-A169-84BCB4195425"><gtr:id>724904C3-EB9D-4C9F-A169-84BCB4195425</gtr:id><gtr:firstName>Theresa</gtr:firstName><gtr:surname>Barnes</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0600404"><gtr:id>39B8691D-BF3D-46A3-AB19-541F9C7AF875</gtr:id><gtr:title>Dysregulated neutrophil function mediates endothelial dysfunction in systemic sclerosis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0600404</gtr:grantReference><gtr:abstractText>Systemic sclerosis (SSc) is a chronic disease that causes a lot of disability and can lead to premature death. The mechanisms that cause this disease are not fully understood and, as a result, treatment is inadequate. It is generally thought that the cells that line blood vessels, endothelial cells, are damaged and dysfunctional in SSc and that this is central to the disease. There is also evidence that the immune system behaves abnormally in SSc, and that this might trigger off or perpetuate the disease. I have identified that neutrophils (a type of white blood cell) are abnormal in this disease. Neutrophils are known to interact with endothelial cells and there is evidence to suggest that they may be capable of damaging the endothelial cell and therefore contribute to disease in SSc. The key goal of this research is to characterise peripheral blood neutrophils in SSc in terms of the proteins that they express and their function.</gtr:abstractText><gtr:technicalSummary>Systemic sclerosis (SSc) is a connective tissue disease with high morbidity and mortality. There is currently no definitive therapy to treat the underlying disease, reflecting the fact that the pathogenesis of SSc is poorly understood - although endothelial cells and leukocytes appear to play an important role. 
We have recently identified two sub-populations of neutrophils in SSc. One responds normally, whilst the other shows defective activation in vitro. This pattern has not been observed before either in healthy individuals or patients with inflammatory disease. Furthermore, in proteomic studies, I have found that SSc neutrophils are activated in vivo.
Neutrophils interact closely with and modulate the function of endothelial cells - both cell types appear abnormal in SSc. It is therefore important to determine if neutrophil-derived mechanisms may contribute to endothelial dysfunction in SSc and identify mechanisms activating this process.
The aim of this project is to characterise neutrophil function in SSc and determine the mechanisms that control this process, focusing on interactions between neutrophils and endothelial cells, to identify novel therapeutic targets in this disease.
The key goals of the research are to:
1. Separate the subpopulations of neutrophils in SSc peripheral blood.
2. Characterise the functional and molecular properties of each subpopulation.
3. Measure endothelin expression by neutrophils in SSc and assess its role in neutrophil: endothelial interaction in this disease.
4. Model neutrophil:endothelial cell interactions in vitro and determine their relevance to the pathogenesis of SSc.

Plan of investigation and scientific procedures: 
First, I will design experimental strategies to separate the two neutrophil sub-populations. Functional properties of these sub-populations will then be determined including: chemotaxis, phagocytosis, respiratory burst activity, rates of apoptosis (both endogenous and in response to agents that accelerate or delay apoptosis), expression of cell surface receptors and ability to generate cytokines and chemokines (both endogenously and in response to activation in vitro). 
I will then use proteomics-based approaches to identify the molecular profiles of the separated sub-populations, and identify changes in expression of membrane-associated proteins. I will measure concentrations of endothelin (ET) expression by neutrophils isolated from SSc patients and determine the role played by this molecule in the regulation of functions described above. Finally, I will model neutrophil:endothelial cell interactions in vitro, measuring endothelial cell viability and function, and determine the roles played by ET and hypoxia in these interactions.</gtr:technicalSummary><gtr:fund><gtr:end>2009-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>186144</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>7CF6A2ED-C9EA-4A75-B167-F4742A7FF6F7</gtr:id><gtr:title>Endothelial activation and apoptosis mediated by neutrophil-dependent interleukin 6 trans-signalling: a novel target for systemic sclerosis?</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76bdfcdf507f8f407fe3eff610bd7cdb"><gtr:id>76bdfcdf507f8f407fe3eff610bd7cdb</gtr:id><gtr:otherNames>Barnes TC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>LuqRRtuA3p8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5DCD3DD3-9A21-43BA-922D-3675B1B4D0D9</gtr:id><gtr:title>Neutrophil-derived reactive oxygen species in SSc.</gtr:title><gtr:parentPublicationTitle>Rheumatology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76bdfcdf507f8f407fe3eff610bd7cdb"><gtr:id>76bdfcdf507f8f407fe3eff610bd7cdb</gtr:id><gtr:otherNames>Barnes TC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn><gtr:outcomeId>pm_540e14ae14a997d9d</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>53CCC012-71EF-4234-8BEF-BED57066CC74</gtr:id><gtr:title>Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol.</gtr:title><gtr:parentPublicationTitle>International journal of nanomedicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9fe6345ca1bc7d3388a8a07010335a5d"><gtr:id>9fe6345ca1bc7d3388a8a07010335a5d</gtr:id><gtr:otherNames>Barnes T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1176-9114</gtr:issn><gtr:outcomeId>A24F16542E8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80F10D01-39E3-4205-931E-2D9B83A09A51</gtr:id><gtr:title>Pharmacokinetic modeling of dynamic contrast-enhanced MRI of the hand and wrist in rheumatoid arthritis and the response to anti-tumor necrosis factor-alpha therapy.</gtr:title><gtr:parentPublicationTitle>Magnetic resonance in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68f1a2893cd9c6db04e07b4be0bf7973"><gtr:id>68f1a2893cd9c6db04e07b4be0bf7973</gtr:id><gtr:otherNames>Hodgson RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0740-3194</gtr:issn><gtr:outcomeId>020DB74BD25</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CFA57E5E-F318-4D65-9995-12A5371B3018</gtr:id><gtr:title>Relative a1-anti-trypsin deficiency in systemic sclerosis.</gtr:title><gtr:parentPublicationTitle>Rheumatology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76bdfcdf507f8f407fe3eff610bd7cdb"><gtr:id>76bdfcdf507f8f407fe3eff610bd7cdb</gtr:id><gtr:otherNames>Barnes TC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn><gtr:outcomeId>A08F6489_BA08F6489_B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0649545-A26E-45AC-A435-A1D2229FD5E9</gtr:id><gtr:title>Neutrophil apoptosis in rheumatoid arthritis is regulated by local oxygen tensions within joints.</gtr:title><gtr:parentPublicationTitle>Journal of leukocyte biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b6f5f3921019c8aec0d288fb8db3e240"><gtr:id>b6f5f3921019c8aec0d288fb8db3e240</gtr:id><gtr:otherNames>Cross A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0741-5400</gtr:issn><gtr:outcomeId>5F787BA78F7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>86BEEA91-AA60-4119-81BE-5CB2E066FB6A</gtr:id><gtr:title>Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril.</gtr:title><gtr:parentPublicationTitle>Arthritis and rheumatism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f7af88217801e6843ddfec9dfdb7a0f4"><gtr:id>f7af88217801e6843ddfec9dfdb7a0f4</gtr:id><gtr:otherNames>Gliddon AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0004-3591</gtr:issn><gtr:outcomeId>EE70ED3C554</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4BBB59B9-B324-434B-A0E0-7B8F566D5C81</gtr:id><gtr:title>Dynamic contrast enhanced MRI of bone marrow oedema in rheumatoid arthritis.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e361ec90d04c8fb617535d27e39d3a10"><gtr:id>e361ec90d04c8fb617535d27e39d3a10</gtr:id><gtr:otherNames>Hodgson R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>1C4FA6D863B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>790472AB-A957-4AC8-BD11-756BF6DD635F</gtr:id><gtr:title>Changes underlying the dynamic contrast-enhanced MRI response to treatment in rheumatoid arthritis.</gtr:title><gtr:parentPublicationTitle>Skeletal radiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68f1a2893cd9c6db04e07b4be0bf7973"><gtr:id>68f1a2893cd9c6db04e07b4be0bf7973</gtr:id><gtr:otherNames>Hodgson RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0364-2348</gtr:issn><gtr:outcomeId>97391772A46</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0600404</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>